Funding for this research was provided by:
Text and Data Mining valid from 2019-11-10
Received: 21 December 2018
Accepted: 13 September 2019
First Online: 10 November 2019
Ethics approval and consent to participate
: This post hoc analysis included data from patients from four double-blind, randomized, placebo- or active-controlled trials of originator adalimumab in patients with RA. The individual studies were performed in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki.The individual study protocols were reviewed and approved by an institutional review board or ethics committee at each study center. All patients provided written informed consent.
: All authors participated in interpreting the data and writing, critically reviewing, and approving the final manuscript and consented to submitting the manuscript.
: JS received grants and consulting fees from AbbVie Inc., AstraZeneca, Janssen, Lilly, Merck Sharpe & Dohme, Pfizer, Roche and consulting fees from Amgen, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Gilead, Glaxo, ILTOO Pharma, Novartis-Sandoz, Samsung, Sanofi, and UCB. RF received research grants and consulting fees from AbbVie. DA received grants and consulting fees from AbbVie, Janssen, Pfizer, and Roche and consulting fees from Amgen, Celgene, Eli Lilly, Merck, Novartis, Sandoz, Sanofi/Genzyme, and UCB. YL, IS, and IL are employees of AbbVie and may own stock/options. YZ is a former employee of AbbVie and may own AbbVie stock/options.